Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betulinic acid is a naturally occurring pentacyclic triterpenoid with demonstrated antiretroviral (anti-HIV), antimalarial, anti-inflammatory and anticancer properties. It is found in the bark of several plant species such as white birch (*Betula pubescens*), ber tree (*Ziziphus mauritiana*), and others. Its anticancer activity is attributed to selective induction of apoptosis in tumor cells via direct activation of the mitochondrial pathway independent of p53 and CD95. Betulinic acid also acts as a TGR5 agonist and has been investigated for its potential cardiovascular role in modulating endothelium-dependent relaxation[2][3][5]. It has been studied in clinical trials for melanoma treatment and dysplastic nevus syndrome[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betulinic acid.